Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bertek Apomorphine Clears FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Bertek Apokyn (apomorphine) clears FDA April 20 for subcutaneous injection to treat "off" episodes of Parkinson's disease

You may also be interested in...



Mylan Apokyn Review Hampered By "Ubiquitous Use" Of Tigan In Trials

FDA's Neuropharm division felt use of the older antiemetic in Parkinson's therapy trials posed "thorny problem" due to lack of chronic experience with Tigan and poorly documented concomitant use. FDA ultimately recommends concomitant antiemetic therapy in labeling, as well as a Phase IV study to determine the "actual necessity" of Tigan in combination with Apokyn.

Mylan Apokyn Review Hampered By "Ubiquitous Use" Of Tigan In Trials

FDA's Neuropharm division felt use of the older antiemetic in Parkinson's therapy trials posed "thorny problem" due to lack of chronic experience with Tigan and poorly documented concomitant use. FDA ultimately recommends concomitant antiemetic therapy in labeling, as well as a Phase IV study to determine the "actual necessity" of Tigan in combination with Apokyn.

Teva Agilect “Approvable” For Parkinson’s Disease

The company is pursuing an indication for rasagiline as monotherapy in early Parkinson’s disease and as adjunct therapy to levodopa in moderate-to-advanced stages of the disease.

Topics

UsernamePublicRestriction

Register

PS059183

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel